News 25.03.2019 SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to...
News 13.03.2019 Schlieren (Zurich), Switzerland, March 13, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate...
News 04.03.2019 ZURICH, Switzerland, March 04, 2019 – NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune. Dr. Dominik Escher, Partner at Pureos Bioventures...
News 11.02.2019 Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal...
News 07.02.2019 Zurich-Schlieren, Switzerland, February 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for...